Datamonitor Healthcare: data analysis and insight

Datamonitor Healthcare

Neuropathic Pain Market and Forecast Analysis to 2026

By Nicola Sawalhi-Leckenby 07 Sep 2018

Big changes are coming to the neuropathic pain market – are you prepared? Take a look at the projected neuropathic pain drug sales for the US, Japan, and five EU nations with the latest infographic from Datamonitor Healthcare. This snapshot view of the future of the neuropathic pain market is packed with data from the full Datamonitor Healthcare Neuropathic Pain Disease Coverage report.

Datamonitor Healthcare

Meningococcal Vaccines Forecast Infographic

By Karolina Kujawa 28 Aug 2018

Over 1.2 million cases of bacterial meningitis are estimated to occur worldwide each year. If not treated promptly, up to half of those cases will be fatal. This infographic from Datamonitor Healthcare provides a snapshot of the meningococcal vaccines market in the US and five major EU markets. What does the meningococcal vaccines market have in store and how will it affect your business? Download now.

Datamonitor Healthcare

Epidiolex and Epilepsy - big changes for medical marijuana

By Stephanie Yip 28 Aug 2018

With the FDA’s landmark approval of Epidiolex, a cannabidiol used to treat rare, severe pediatric epilepsies, the only obstacle to the legal sale of the drug is DEA reclassification of cannabidiol (CBD). With reclassification likely in the next 90 days, what does it mean for the epilepsy market, as well as the wider market for CBD?

Datamonitor Healthcare

Japan Pharma Outlook 2027 Report Extract

27 Aug 2018

Download your complimentary Japan Pharma Outlook 2027 report extract. The 16-page excerpt includes highlights from the full report, which is available to subscribers of Datamonitor Healthcare, and available to purchase on our Report Store. Discover now the complex challenges and opportunities facing Japan Pharma.

Datamonitor Healthcare

Trends in Gene Therapy Seminar

By Patricia Reilly 22 Aug 2018

The promises of gene therapy are taking a long time to be fulfilled, in part due to challenges in developing gene vectors capable of safe and efficient delivery of therapeutic genes (transgenes) into patients’ cells. Nonetheless, these challenges are being addressed in innovative ways. A variety of first-generation vectors, both viral and non-viral, have been employed in clinical trials with varying degrees of success, and the experience gained is guiding the design of next-generation vectors.

Datamonitor Healthcare

Podcast - Analyst Opinion on Approval of AndexXa for reversal of Eliquis and Xarelto

By Zachary McLellan 22 Aug 2018

Zach McLellan, Jack Allen, and guest analyst Cameron Findlater discuss current events in the healthcare space in the Datamonitor Healthcare Analyst Podcast, including the approval of AndexXa for reversal of Eliquis and Xarelto & Eli Lilly's acquisition of ARMO Biosciences.

Datamonitor Healthcare

Japan Pharma Outlook Webinar Recording

By Ian Haydock 22 Aug 2018

Listen to this insightful presentation of the unique challenges and opportunities faced by Japan Pharma, hosted by the expert analysts from Pharma Intelligence.

Datamonitor Healthcare

Datamonitor Healthcare Analyst Podcast: Post-ASCO Podcast 2

By Jack Allen 22 Aug 2018

Zach McLellan and Jack Allen are joined by guest analyst Maria Berezina. The group discusses key recent events that occurred at the American Society of Clinical Oncology 2018 Annual Meeting.

Datamonitor Healthcare

Datamonitor Healthcare Analyst Podcast: Post-ASCO Podcast 1

By Jack Allen 22 Aug 2018

Zach McLellan and Jack Allen are joined by guest analysts Dominique Fontanilla and Hardik Patel. The group discusses key recent events that occurred at the American Society of Clinical Oncology 2018 Annual Meeting.

Datamonitor Healthcare

Business Development and Licensing Video

01 Jul 2018

If you’re a senior business development and licensing professional in pharma or biotech, it’s your job to ensure that your company’s revenue pipeline is full of viable opportunities and accelerate growth for your organisation. Watch this short video  and discover how Informa’s Pharma Intelligence provides the rock-solid intelligence you need to accelerate growth and drive business forward.

Datamonitor Healthcare

Acute Myeloid Leukemia Market Outlook Seminar

By Dominique Fontanilla 27 Jun 2018

There has been little change to standard treatment for AML in recent years; however, 2017 saw a flurry of new targeted drug approvals, sparking significant market growth. Patient age remains the biggest factor in driving treatment decisions for AML. Cases of AML are expected to increase, and prognosis remains poor – especially among older adults. Drug developers are targeting patient segments with high unmet clinical need to gain access to the AML market and the budget impact of AML is expected to grow considerably.

Datamonitor Healthcare

Approval of Sun Pharmas Yonsa in Prostate Cancer Podcast

By Zachary McLellan 29 May 2018

Zach McLellan and Jack Allen discuss current events in the healthcare space in the Datamonitor Healthcare Analyst Podcast, including the approval of Sun Pharma's Yonsa in prostate cancer, and broad market commentary on Tesaro, Gilead, Clovis, Portola, BMS and Celgene

Citeline, Scrip, Biomedtracker, Datamonitor Healthcare

ASCO Essentials Webinar 2018 Recording

By Mary Jo Laffler 29 May 2018

Just in time for your 2018 ASCO Annual Meeting planning, join analysts from Datamonitor Healthcare, Biomedtracker, Citeline, Scrip, and Pink Sheet for their expert opinions on what you need to know to get the most from the meeting. Let our experts present their top picks from the thousands of abstracts being presented at ASCO.

Datamonitor Healthcare

Profitability Assessment of Branded Generic Inhalers

By Ljlal Syed, Mark Lansdell and David Abramson 17 May 2018

This report examines the extent to which order of market entry influences the prospects of achieving a satisfactory return on investment for companies developing branded generic

Datamonitor Healthcare

Gene therapy

15 May 2018